Indeed, results from in vivo experiments demonstrated that RosA treatment effectively reduced H1N1 virus-mediated lung injury, while blockade of h-PGDS was unexpected to completely reverse these protective effects of RosA, supporting the idea that h-PGDS activation could act as a suitable target for influenza illness. This evidence concerns the gene HPGDS and influenza.